Evrysdi – Risdiplam

Lien vers plus d’informations

Disponible:

À compter du 1er juin 2022, selon le Bulletin 118, EVRYSDI® (risdiplam) est couvert par le programme de médicaments du Manitoba (Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary) (lien). Les critères particuliers de remboursement sont conformes aux recommandations émises par l’ACTMS (Agence canadienne des médicaments et des technologies de la santé) en 2021 et sont offerts sur demande auprès du service de l’EDS au sein de Santé Manitoba.

Spinraza – Nusinersen

https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin102.pdf

Available:

Initiation Criteria
1. Pre-symptomatic patients with two or three copies of the SMN2 gene, OR

2. Had the disease for <6 months, two copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age; OR 3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently.†

Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement on HINE-2, CHOP INTEND, or HFMSE, OR

2. For those symptomatic at initiation: no improvement in HINE-2, CHOP INTENT, or HFMSE, OR

3. Permanent invasive ventilation required

“Other patients who do not meet the expanded funding criteria may be considered in exceptional cases.”